Recent news coverage does not include company-specific business developments but includes general market and sector-related headlines from www.nasdaq.com.

• Protagenic Therapeutics, Inc. has no recent company-specific news coverage in the primary business news sources [N1].
• Recent market news includes various companies crossing key moving average levels and commodity price movements, but none directly relate to Protagenic [N1][N2][N3][N4][N5][N6][N7][N8].

Protagenic's lead compound PT00114 targets a large and underserved market of stress-related neuropsychiatric disorders with significant unmet medical needs. The novel mechanism of action and positive preclinical data support potential differentiation from existing therapies. Completion of Phase I trials and planned Phase II studies mark important clinical milestones. Exclusive licensing agreements and a growing intellectual property portfolio provide a foundation for future development. The company's strategy to develop additional TCAP family compounds could expand its therapeutic offerings. Collaboration with expert clinical investigators enhances trial design and execution [S1].

Protagenic is an early-stage biopharmaceutical company with no approved products or commercial revenues, operating at a net accumulated deficit. It faces substantial risks including the need for additional financing, regulatory approval uncertainties, and competition from larger, more established companies. The company lacks sales and marketing capabilities and depends on third-party manufacturers and collaborators. Its common stock is delisted from Nasdaq and trades on the OTCQB, reflecting liquidity and market perception challenges. Clinical trial outcomes remain uncertain, and the company may not achieve profitability or commercial success [S1][S2].

Protagenic's moat is primarily based on its proprietary, patent-protected lead compound PT00114 and exclusive licensing agreements with the University of Toronto, which provide worldwide rights to a novel neuropeptide therapeutic targeting stress-related disorders. The unique mechanism of action of PT00114, supported by extensive peer-reviewed research and preclinical efficacy, differentiates it from existing treatments. The company also develops follow-on compounds in the TCAP family, potentially broadening its pipeline. However, the company faces competition from larger pharmaceutical firms with greater resources and experience, and its early clinical-stage status means its intellectual property and clinical advantages are yet to be fully validated in human trials [S1].

• Clinical Development Risk: Protagenic's lead compound PT00114 is in early clinical stages; failure to demonstrate safety or efficacy in ongoing or future trials could delay or prevent regulatory approval.
• Financing Risk: The company has a limited operating history and an accumulated deficit, requiring additional capital to fund operations and clinical development; inability to secure financing could impair progress.
• Regulatory Risk: Obtaining regulatory approvals involves complex processes with uncertain outcomes; delays or denials could adversely affect the company's business.
• Competition Risk: Protagenic competes with larger pharmaceutical companies with greater resources and experience, which may limit its market opportunities.
• Operational Risk: The company relies on third-party manufacturers and collaborators; disruptions or inability to establish sales and marketing infrastructure could hinder commercialization.
• Market and Liquidity Risk: Delisting from Nasdaq and trading on OTCQB reduces liquidity and may affect investor confidence and stock price stability.

• Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders [S1].
• The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 (TCAP-1), an endogenous brain signaling peptide that dampens overactive stress responses [S1].
• PT00114 has demonstrated efficacy in preclinical animal models for depression, anxiety, substance abuse and addiction, and PTSD, working through a novel mechanism of action [S1].
• Protagenic holds exclusive worldwide rights to PT00114 through a license agreement with the University of Toronto and rights to additional intellectual property from Dr. David Lovejoy's laboratory [S1].
• The company is developing follow-on compounds in the TCAP family to build a pipeline of assets with differentiated features [S1].
• Preclinical work to begin clinical trials was completed in the first half of 2023; the first human trial started on September 26, 2023 [S1].
• Phase I trial single-dose portion results were announced on May 22, 2024; multiple-dose portion completed in December 2025 [S1].
• A Phase 2 study is planned to begin in late 2026 to evaluate PT00114 in patients with chronic stress-related psychiatric disorders [S1].
• The clinical development program is led by Dr. Maurizio Fava, a recognized expert in psychiatric disorders [S1].
• The Phase I/IIa study evaluates safety, tolerability, and early activity of PT00114 in healthy volunteers and patients with psychiatric illnesses, starting with Generalized Anxiety Disorder (GAD) [S1].
• Subsequent cohorts include patients with Major Depressive Disorder (MDD), Substance Use Disorder (SUD), and Post-Traumatic Stress Disorder (PTSD) with suboptimal response to existing treatments [S1].
• The company stratifies patients by corticosterone levels to identify those more likely to benefit from treatment, linking preclinical and clinical studies [S1].
• The market for stress-related neuropsychiatric disorders is large with significant unmet medical need and limited effective treatments [S1].
• Protagenic has no sales, marketing, or distribution capabilities currently and plans to develop or collaborate for these functions as clinical development progresses [S1].
• The company relies on third-party contract manufacturers for synthesis of PT00114 under cGMP conditions; the compound is stable for at least 12 months [S1].
• Initial dosage form is a subcutaneous injection; other routes such as sublingual or intranasal are being developed [S1].
• Protagenic entered into and subsequently unwound a reverse merger with Phytanix Bio during the year ended March 31, 2026, limiting comparability of financials [S1].
• As of March 31, 2026, Protagenic had cash and equivalents of $191,674, current assets of $1,542,586, current liabilities of $1,031,479, a current ratio of 1.5, and a cash ratio of 0.19 [S2].
• The company reported net income of $1,367,977 and earnings per share of $0.59 for the year ended March 31, 2026, but has an accumulated deficit of $4,029,629 [S1].
• Protagenic has no products generating revenue and does not expect to generate commercial revenues in the near future [S1].
• The company faces risks including limited operating history, need for additional financing, regulatory approval challenges, competition from larger firms, and reliance on third parties for manufacturing and clinical trials [S1].
• Protagenic's common stock was delisted from Nasdaq effective January 5, 2026, and now trades on the OTCQB market under the symbol PTIX [S1].